BioNtech swallows MAB Discovery antibody unit
Immunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discoverys antibody generation unit.
Clariant inks cellulosic biodiesel pact with ExxonMobil/REG
Swiss fine chemicals specialist Clariant has hammered out a R&D pact with ExxonMobil and Renewable Energy Group (REG) Inc to combine technologies in order of producing biodiesel from cellulose
IMI launches 80m call
The Innovative Medicines Initiative II has earmarked 80m for pre-competetive research improving the pharmaceutical industry’s productivity.
Boehringer expands neurology activities
Boehringer Ingelheim has expanded its 2014 R&D collaboration with the BioMed X Innovation Center (Heidelberg, Germany) to find new treatment approaches for early intervention of psychiatric diseases.
New target for lung fibrosis discovered
Canadian and Finnish researchers have demonstrated that long immune cell contact to lung tissue turns tissue repair into fibrosis.
Valneva inks $59m JE vaccine supply contract
French vaccine specialist Valneva SE has inked a supply contract with the US Department of Defense for IXIARO its Japanese encephalitis (JE).
VTT turn waste into biofuels and chemicals
Researchers at VTT Technical Research Centre of Finland Ltd have presented a new gasification-based technique to turn forest industry byproducts into transport fuels and chemicals.
Tissue specific tumour transition needs few cells
German researchers have modeled when cellular alterations inevitably lead to the development of cancer. The transition is tissue-specific and needs only a few cells.
Drug dissociates metastasis precursors in blood
A team of Swiss researchers has identified Na+/K+-ATPase blockers as candidate drugs capable to prevent formation of metastases. In blood, the repurposed drugs identified in a screening dissociated clusters of circulating tumour cells (CTCs), forerunners of metastases.